A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Primary Analysis ◽

Abstract OT2-05-01: A phase II randomized trial of gemcitabine plus cisplatin(GP) vs. gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple negative breast cancer

10.1158/1538-7445.sabcs17-ot2-05-01 ◽

2018 ◽

Author(s):

C Gong ◽

E Cao ◽

Z Wang ◽

J Zhang ◽

L Wang ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Phase Ii ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz100.047 ◽

2019 ◽

Vol 30 ◽

pp. iii63

Author(s):

V. Boni ◽

C. Alemany ◽

J.L. Meisel ◽

R. Sinha ◽

D. Sterrenberg ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase Ib ◽

Open Label Phase ◽

OT3-01-08: Phase II Study of S-1 Combined with Cisplatin in the First-Line Treatment of Triple Negative Breast Cancer.

10.1158/0008-5472.sabcs11-ot3-01-08 ◽

2011 ◽

Author(s):

Y Fan ◽

BH Xu

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

10.1158/1538-7445.sabcs19-pd1-06 ◽

2020 ◽

Cited By ~ 2

Author(s):

Hyo (Heather) Han ◽

Sami Diab ◽

Carlos Alemany ◽

Reva Basho ◽

Ursa Brown-Glaberman ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase 1B ◽

IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps1104 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS1104-TPS1104 ◽

Cited By ~ 8

Author(s):

Leisha A. Emens ◽

Sylvia Adams ◽

Sherene Loi ◽

Andreas Schneeweiss ◽

Hope S. Rugo ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Triple Negative ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps1146 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS1146-TPS1146 ◽

Cited By ~ 1

Author(s):

Denise A. Yardley ◽

Adam Brufsky ◽

Robert E. Coleman ◽

Pier Franco Conte ◽

Javier Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

TRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz242.076 ◽

2019 ◽

Vol 30 ◽

pp. v138

Author(s):

A.H. Awada ◽

J. Cortés ◽

S. Slater ◽

I. Macpherson ◽

T. Csoszi ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Locally Recurrent ◽

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

Trials ◽

10.1186/s13063-016-1195-6 ◽

2016 ◽

Vol 17 (1) ◽

Author(s):

Denise A. Yardley ◽

Adam Brufsky ◽

Robert E. Coleman ◽

Pierfranco F. Conte ◽

Javier Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Controlled Trial ◽

Phase Ii ◽

Triple Negative ◽

Controlled Trial ◽

Line Treatment ◽

First Line ◽

Randomized Controlled ◽

P5-19-04: Results of a Randomized Phase II Study Demonstrate Benefit of Platinum-Based Regimen in the First-Line Treatment of Triple Negative Breast Cancer (TNBC).

10.1158/0008-5472.sabcs11-p5-19-04 ◽

2011 ◽

Author(s):

Y Fan ◽

BH Xu ◽

P Yuan ◽

JY Wang ◽

F Ma ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Abstract P3-13-07: A-TaXel: Multicenter phase II combination of bevacizumab (A) with weekly paclitaxel (Ta) and capecitabine (Xel) in first line treatment for patients with triple negative metastatic or locally advanced breast cancer (TNMBC), a GINECO study

10.1158/0008-5472.sabcs13-p3-13-07 ◽

2013 ◽

Author(s):

J-M Ferrero ◽

A-C Hardy-Bessard ◽

O Capitain ◽

A Lortholary ◽

B Salles ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽